NCT04286750View on ClinicalTrials.gov

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 11, 2020

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions
Healthy
Interventions
DRUG

ACT-1004-1239

ACT-1004-1239 administered as hard capsules for oral use.

DRUG

Placebo

Matching placebo administered as hard capsules for oral use.

Trial Locations (1)

4250-449

BlueClinical Phase 1 Hospital de Prelado, Porto

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT04286750 - Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239 | Biotech Hunter | Biotech Hunter